Despite promising results in some specific indications, only a subset of patients respond to treatment for most cancers with PD-1 and CTLA-4 checkpoint inhibitors, and ICI therapy achieves durable responses only in approximately 20–40% of patients, exerting the greatest benefits in patients with melanoma and Hodgkin lymphoma [22]. Here, CTLA4 is linked to melanoma.